代谢功能障碍相关脂肪性肝病缓解可减轻中国青少年亚临床心血管损害
该研究基于桓台儿童心血管健康队列(HCCHC),探讨青少年代谢功能障碍相关脂肪性肝病(MASLD)在2年随访中转归为非MASLD后,能否减轻相关的亚临床心血管损害(颈动脉内膜中层厚度增高和左心室肥厚)。
要点
- MASLD全球估计影响13%的普通儿科人群和47%的肥胖青少年。
- 研究利用HCCHC队列数据,分析2年随访中MASLD转归与亚临床心血管损害的关系。
- 原文未报告具体转归率和心血管损害变化数值。
核心结论
- 研究旨在探讨青少年MASLD在2年随访中转归为非MASLD是否可减轻相关的亚临床心血管损害。
研究设计与样本
- 基于桓台儿童心血管健康队列(HCCHC)研究的数据,随访2年,分析MASLD转归与亚临床心血管损害的关系。
主要发现
- 原文未报告具体研究结果数值。
关键数值与推荐
- 亚临床心血管损害定义为颈动脉内膜中层厚度(cIMT)增高和左心室肥厚(LVH)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease among youths,1,2 affecting an estimated 13% of the general pediatric population and 47% of those with obesity worldwide.3 The disease often progresses from simple steatosis to metabolic dysfunction-associated steatohepatitis, fibrosis, cirrhosis, and ultimately hepatic failure. MASLD also exerts significant burdens on extrahepatic organs, particularly the cardiovascular system. Several prior studies have reported a positive association between MASLD and subclinical cardiovascular damage in youths.4,5 However, it remains largely unknown whether the detrimental cardiovascular effects of MASLD in youths are permanent or reversible. Herein, using data from the Huantai Childhood Cardiovascular Health Cohort (HCCHC) study, we aimed to investigate whether a transition from MASLD to non-MASLD over a 2-year follow-up could alleviate associated subclinical cardiovascular damage (ie, elevated carotid intima-media thickness [cIMT] and left ventricular hypertrophy [LVH]) in youths.
引用
- Yang L, Qiao Y, Zhao M, et al. Resolving Metabolic Dysfunction-Associated Steatotic Liver Disease Reduces Subclinical Cardiovascular Damage in Chinese Youths. Clin Gastroenterol Hepatol. 2025. PMID: 40058748. doi:10.1016/j.cgh.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。